

Carlos Antonio Duarte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/147730/publications.pdf>

Version: 2024-02-01

10
papers

88
citations

1478505

6
h-index

1588992

8
g-index

10
all docs

10
docs citations

10
times ranked

132
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Vimentin as a Potential Therapeutic Target against HIV Infection. <i>Viruses</i> , 2016, 8, 98.	3.3	24
2	Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector. <i>Vaccine</i> , 2001, 20, 961-971.	3.8	23
3	The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates. <i>Vaccine</i> , 1999, 17, 2311-2319.	3.8	15
4	Isolates from Four Different HIV Type 1 Clades Circulating in Cuba Identified by DNA Sequence of the C2-V3 Region. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 55-58.	1.1	10
5	Modified vaccinia virus Ankara (MVA) priming and fowlpox virus booster elicit a stronger CD8 ⁺ T cell response in mice against an HIV-1 epitope than does a DNA/poxvirus prime-booster approach. <i>Biotechnology and Applied Biochemistry</i> , 2004, 39, 313-318.	3.1	7
6	Humoral and cellular immune response in mice induced by the classical swine fever virus E2 protein fused to the porcine CD154 antigen. <i>Biologicals</i> , 2018, 52, 67-71.	1.4	7
7	Cell Penetration and Secondary Structure of a Synthetic Peptide with Anti-HIV Activity. <i>International Journal of Peptide Research and Therapeutics</i> , 2017, 23, 531-539.	1.9	1
8	An improved method for purification and refolding of recombinant HIV Vif expressed in <i>Escherichia coli</i> . <i>Biotechnology and Applied Biochemistry</i> , 2018, 65, 195-202.	3.1	1
9	A competitive ELISA for the quantitative determination of the novel anti-HIV drug candidate CIGB-210 in biological fluids. <i>Journal of Immunoassay and Immunochemistry</i> , 2019, 40, 193-213.	1.1	0
10	Preliminary safety assessment of CIGB-210, an investigational peptide for HIV infection. <i>Human and Experimental Toxicology</i> , 2022, 41, 096032712110737.	2.2	0